Quotidian Technical Highlights on Selected Biotech Stocks -- Juno Therapeutics, Acorda Therapeutics, Lexicon Pharma, and FibroGen

Thursday, January 4, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 4, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment

community. Today we are offering reports on JUNO, ACOR, LXRX, and FGEN which can be accessed for free by signing up to www.wallstequities.com/registration. Forbes reported that US Biotechnology stocks had a very good year in 2017, with the NASDAQ
Biotech Index up 21%. But the sector in Europe ended flat for the year, leading some savvy investors to conclude that European biotechs may be a more compelling play in 2018. Today, WallStEquities.com features the recent performance of four players in this industry: Juno Therapeutics Inc. (NASDAQ: JUNO), Acorda Therapeutics Inc. (NASDAQ: ACOR), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), and FibroGen Inc. (NASDAQ: FGEN). All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration

Juno Therapeutics

On Wednesday, shares in Seattle, Washington headquartered Juno Therapeutics Inc. recorded a trading volume of 1.24 million shares. The stock ended at $48.09, rising 1.56% from the last trading session. The Company's shares have gained 6.63% over the previous three months and 146.74% over the past year. The stock is trading above its 200-day moving average by 35.38%. Furthermore, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 45.44. 

On December 06th, 2017, Juno Therapeutics (JUNO) announced three license agreements to advance the Company's program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. Through its agreement with Eli Lilly and Company, JUNO will acquire a license to the GSI known as LY3039478, a product candidate that has been studied in 411 patients and healthy volunteers. Through its agreements with OncoTracker and Fred Hutchinson Cancer Research Center, JUNO will gain exclusive rights to intellectual property within the field of combinations of GSIs and BCMA-directed engineered T cells.

On December 12th, 2017, research firm Wells Fargo downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Get the full research report on JUNO for free by clicking below at: www.wallstequities.com/registration/?symbol=JUNO

Acorda Therapeutics

Ardsley, New York headquartered Acorda Therapeutics Inc.'s stock finished yesterday's session 3.31% lower at $21.90 with a total trading volume of 644,164 shares. The Company's shares have gained 5.29% in the last month and 12.31% over the past year. The stock is trading above its 200-day moving average by 4.42%. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 48.18. 

On December 26th, 2017, Acorda Therapeutics announced that Ron Cohen, M.D., President and CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 10th, 2018, at 12:30 p.m. EST in San Francisco. A live audio webcast of the presentation can be accessed under the "Investor Events" section of the Company's website. The free technical report on ACOR can be accessed at: www.wallstequities.com/registration/?symbol=ACOR

Lexicon Pharmaceuticals

At the close of trading on Wednesday, shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. jumped 3.66%, ending the day at $10.49. The stock recorded a trading volume of 1.03 million shares, which was above its three months average volume of 756,040 shares. The Company's shares have advanced 0.38% in the last one month. The stock is trading 4.41% above its 50-day moving average. Moreover, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 55.96. 

On January 02nd, 2018, Lexicon Pharma announced that Lonnel Coats, President and CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 09th, 2018, at 8:30 a.m. PST in San Francisco, California. A live audio webcast for this conference will be available under the "Investors" section of the Company's website.  Sign up for free on Wall St. Equities and claim the latest report on LXRX at: www.wallstequities.com/registration/?symbol=LXRX


San Francisco, California headquartered FibroGen Inc.'s shares ended the day 0.79% lower at $50.30 with a total trading volume of 381,274 shares. The stock has gained 6.68% in the last month and 136.15% over the past year. The Company's shares are trading 3.47% above their 50-day moving average and 27.82% above their 200-day moving average. Additionally, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the US, have an RSI of 59.83. See the free research coverage on FGEN at: www.wallstequities.com/registration/?symbol=FGEN


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----juno-therapeutics-acorda-therapeutics-lexicon-pharma-and-fibrogen-300577502.html

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store